1. In Vivo
  2. >>Market Access

Podcast: Navigating Challenges – The Changing Role Of Big Pharma

Podcast Interview With AstraZeneca's Stefan Woxström

 
• By Lucie Ellis-Taitt

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

In Vivo Podcast
• Source: Shutterstock

"I have to go beyond just focusing on bringing medicine to patients but also start looking at what health care systems really need."

In this latest instalment of the In Vivo podcast, Stefan Woxström, senior VP of AstraZeneca, Europe and Canada, draws attention to the role big pharma can adopt in delivering preventative and sustainable health care. Woxström analyzes the changing role of technology in disease prevention and looks forward to the future of AstraZeneca. 

Timestamps:

Introduction - 00:00

What concerns do you hold for the future of health care? - 4:50 

How does big pharma need to act to protect innovation? – 7:20 

Role within preventative health- 11:56

Devices in medicine- 16:17

Goals for the business in the next 12-18 months- 22:04

How will work adapt to achieve these aims? - 24:00

More from Market Access

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By David Wild

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.